# Recurrent and Non-Recurrent Copy Number Variants in Native Americans and a Cosmopolitan Sample in Relation to Alcohol Use Disorder and Other Psychiatric Diseases

**Authors:** Salma M Wakil, Keita Morisaki, Pei-Hong Shen, Dylan G Sucich, Melanie Schwandt, James Fielding Hejtmancik, Cheryl Marietta, Qiaoping Yuan, Nancy Diazgranados, Colin A Hodgkinson, David Goldman

PMC · DOI: 10.1007/s12035-026-05808-w · Molecular Neurobiology · 2026-03-23

## TL;DR

The study explores copy number variants in Native American populations to understand their link to alcohol use disorder and psychiatric diseases.

## Contribution

The paper identifies recurrent CNVs in Native Americans and examines their potential role in psychiatric disorders despite limited predictive power.

## Key findings

- Recurrent CNVs were found in Native American tribes, with some shared across geographically and linguistically distinct groups.
- A specific CNV on chromosome 6p21.33 showed haploinsufficiency of two genes but did not predict psychiatric outcomes after multiple testing correction.
- A CNV in the 22q11.2 region showed nominally elevated odds ratios for alcohol use disorder and psychiatric diagnosis but was not statistically significant after correction.

## Abstract

Copy number variants (CNVs) can alter disease susceptibility by gene deletion, duplication, and other mechanisms, and have been implicated in neuropsychiatric diseases. However, their rarity or de novo nature impedes linkage analysis. Therefore, we identified recurrent CNVs (rCNVs) in Native Americans with low genetic admixture and high prevalence of alcohol use disorder (AUD) and other psychiatric disorders. Large (> 200 kb) rCNVs were abundant in Plains Indians (PI) and Southwest American Indians (SWI), almost all carrying at least one rCNV, with some CNVs found in both geographically and linguistically distinct tribes. In patients carrying rCNVs, gene deletions led to haploinsufficiency, and duplications led to increased gene dosage. Haplotype analysis revealed a common chromosome 6p21.33 recurrent CNV (rCNV) that persisted in Native Americans for at least 750 generations, leading to haploinsufficiency of at least two genes. Gene-based CNV burden and CNV count did not predict AUD or other psychiatric disorders. However, an rCNV, found in PI and duplicating three genes within the 22q11.2 velocardiofacial syndrome region, showed nominally elevated odds ratios in generalized linear mixed models accounting for kinship as a random effect and age and sex as fixed covariates. For AUD, the odds ratio was 3.19 (95% CI 1.12–9.07, p = 0.03), and for psychiatric diagnosis, the odds ratio was 4.80 (95% CI 1.37–16.82, p = 0.014). These associations, calculated with adjustment for relatedness, did not remain statistically significant after correction for multiple testing, illustrating the challenge of linking CNVs to behavior even if they are recurrent and potentially of large effect. The effects of most CNVs are undetectable via genome-wide association studies with single SNPs, and in cosmopolitan populations, most CNVs are nonrecurrent, sometimes affecting similar genomic regions but differing in their properties, and origins. Recurrent CNVs having ancient origins are prevalent in Native American populations providing an opportunity to examine their relationships to disease risk. However, we observed that neither gene-based CNV burden nor individual rCNVs did not predict AUD or other psychiatric outcomes, after adjustment for the numbers of rCNVs tested.

The online version contains supplementary material available at 10.1007/s12035-026-05808-w.

## Full-text entities

- **Genes:** IMMP2L (inner mitochondrial membrane peptidase subunit 2) [NCBI Gene 83943] {aka IMMP2L-IT1, IMP2, IMP2-LIKE}, GSTK1 (glutathione S-transferase kappa 1) [NCBI Gene 373156] {aka GST, GST 13-13, GST13, GST13-13, GSTK1-1, hGSTK1}, DGCR6 (DiGeorge syndrome critical region gene 6) [NCBI Gene 8214], ADH1B (alcohol dehydrogenase 1B (class I), beta polypeptide) [NCBI Gene 125] {aka ADH2, HEL-S-117}, HTR2B (5-hydroxytryptamine receptor 2B) [NCBI Gene 3357] {aka 5-HT(2B), 5-HT-2B, 5-HT2B}, ALDH2 (aldehyde dehydrogenase 2 family member) [NCBI Gene 217] {aka ALDH-E2, ALDHI, ALDM}, WDTC1 (WD and tetratricopeptide repeats 1) [NCBI Gene 23038] {aka ADP, DCAF9}, SNX31 (sorting nexin 31) [NCBI Gene 169166], HCP5 (HLA complex P5) [NCBI Gene 10866] {aka 6S2650E, D6S2650E, P5-1}, ANKRD46 (ankyrin repeat domain 46) [NCBI Gene 157567] {aka ANK-S, GENX-115279}, MACROD2 (mono-ADP ribosylhydrolase 2) [NCBI Gene 140733] {aka C20orf133, C2orf133}, Prodh (proline dehydrogenase) [NCBI Gene 19125] {aka Pro-1, Pro1, Ym24d07}, TBX1 (T-box transcription factor 1) [NCBI Gene 6899] {aka CAFS, CATCH22, CTHM, DGCR, DGS, DORV}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, HCG26 (HLA complex group 26) [NCBI Gene 352961] {aka 3.8-1, NCRNA00191, bCX205D4.4, bPG181B23.4}, PRODH (proline dehydrogenase 1) [NCBI Gene 5625] {aka HSPOX2, PIG6, POX, PRODH1, TP53I6}, Inhca (inhibitor of carbonic anhydrase) [NCBI Gene 71775] {aka 1300017J02Rik, Ica, mICA}, NRXN1 (neurexin 1) [NCBI Gene 9378] {aka Hs.22998, PTHSL2, SCZD17}, ACTL8 (actin like 8) [NCBI Gene 81569] {aka CT57}, USP18 (ubiquitin specific peptidase 18) [NCBI Gene 11274] {aka ISG43, PTORCH2, UBP43}
- **Diseases:** autism spectrum disorder (MESH:D000067877), autoimmune disorders (MESH:D001327), conditions (MESH:D020763), heritable diseases (MESH:D065627), PTSD (MESH:D013313), DSM (MESH:D001714), cancer (MESH:D009369), haploinsufficiency of 30-50 genes (OMIM:614891), SCID (MESH:D020914), anxiety (MESH:D001007), PI (MESH:C562580), Trisomy 21 (MESH:D004314), congenital abnormalities (MESH:D000013), genetic diseases (MESH:D030342), MDD (MESH:D003865), ADHD (MESH:D001289), plague (MESH:D010930), Schizophrenia (MESH:D012559), DSM-III-R (MESH:C580424), 22q11.21 (MESH:D058165), facial dysmorphism (MESH:C565579), BAF (MESH:D006509), developmental delay (MESH:D002658), malaria (MESH:D008288), phobia (MESH:D010698), cardiac anomalies (MESH:D006331), ASD (MESH:D001321), neuropsychiatric disease (MESH:D004194), epilepsy (MESH:D004827), 22q11.2 velocardiofacial syndrome (MESH:D004062), depression (MESH:D003866), ASPD (MESH:D000987), type I diabetes (MESH:D003922), Alcohol Use Disorder (MESH:D000437), CNV (MESH:D000092342), ID (MESH:D008607), OCD (MESH:D009771), SUD (MESH:D019966), anxiety disorder (MESH:D001008), Psychiatric (MESH:D001523), Prader-Willi (MESH:D011218), cognitive deficits (MESH:D003072), impulsivity (MESH:D007174), 22q11.21 duplications (MESH:C567224), neurodegenerative diseases (MESH:D019636), GLMM (MESH:D004195)
- **Chemicals:** lactose (MESH:D007785), mono (MESH:C106553), glutamate (MESH:D018698), proline (MESH:D011392), PI (-)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]
- **Cell lines:** NIH CC — Homo sapiens (Human), Embryonic stem cell (CVCL_9T86)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13006474/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13006474/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC13006474/full.md

---
Source: https://tomesphere.com/paper/PMC13006474